Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo ...

Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.

Tectonic Therapeutic Inc ( (TECX) ) has released its Q3 earnings. Here is a breakdown of the information Tectonic Therapeutic ...

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...

Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its ...

The two-year-old South San Francisco-based biotech – which focuses on the development of small-molecule drugs targeting G ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...